Back to top

Image: Bigstock

Geron Corporation

Read MoreHide Full Article

Geron is positive on its agreement with J&J for imetelstat, which provides it with a strong partner as well as funds. In Apr 2017, Geron/J&J reported positive interim update on Imetelstat. Geron clarified that for IMerge, the benefit/risk profile of imetelstat in the treated patients supports continued development in lower risk MDS indication. Moreover, for IMbark, the recent results suggest that the clinical benefit and a potential overall survival benefit observed supports continuation of the trial without modifications. However, Geron's dependence on a single pipeline candidate imetelstat raises concerns. The company’s shares have underperformed the Zacks classified Medical-Biomedical/Genetics industry in the last one year. Estimates have been stable lately ahead of the company’s Q1 earnings release. The company has positive record of earnings surprises in recent quarters.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Geron Corporation (GERN) - free report >>

Published in